Real-world efficacy

Intravenous palonosetron three-drug regimen for chemotherapy-induced nausea and vomiting with highly emetogenic chemotherapy

Lee Schwartzberg, Trent McLaughlin, Robert B. Geller, Nashat Y. Gabrail, Stanley M. Marks

Research output: Contribution to journalArticle

Abstract

Aim: Real-world palonosetron effectiveness was evaluated in an antiemetic regimen with highly emetogenic chemotherapy (HEC). Patients & methods: In this Phase IV, prospective, multicenter observational study, HEC-treated cancer patients received palonosetron, a neurokinin 1 receptor antagonist, and dexamethasone. Primary objective was to assess complete response (CR) for acute (≤24 h), delayed and overall (≤120 h) chemotherapy-induced nausea and vomiting. Results: Of 159 patients, 65.4% had breast cancer, 64.8% received anthracycline (doxorubicin)-plus-cyclophosphamide-containing chemotherapy; 155 completed one HEC cycle. CR was 60.0% acute, 39.4% delayed and 34.8% overall, and then increased (all phases) in 69 patients completing four HEC cycles. Anthracycline (doxorubicin) plus cyclophosphamide-receiving patients had especially low CR. Conclusion: Even within a recommended three-drug antiemetic regimen, palonosetron may provide suboptimal chemotherapy-induced nausea and vomiting control with HEC in real-world settings.

Original languageEnglish (US)
Pages (from-to)1161-1170
Number of pages10
JournalJournal of Comparative Effectiveness Research
Volume7
Issue number12
DOIs
StatePublished - Dec 1 2018

Fingerprint

Nausea
Vomiting
Drug Therapy
Pharmaceutical Preparations
Antiemetics
Anthracyclines
Doxorubicin
Cyclophosphamide
Neurokinin-1 Receptor Antagonists
palonosetron
Dexamethasone
Multicenter Studies
Observational Studies
Breast Neoplasms
Neoplasms

All Science Journal Classification (ASJC) codes

  • Health Policy

Cite this

Real-world efficacy : Intravenous palonosetron three-drug regimen for chemotherapy-induced nausea and vomiting with highly emetogenic chemotherapy. / Schwartzberg, Lee; McLaughlin, Trent; Geller, Robert B.; Gabrail, Nashat Y.; Marks, Stanley M.

In: Journal of Comparative Effectiveness Research, Vol. 7, No. 12, 01.12.2018, p. 1161-1170.

Research output: Contribution to journalArticle

@article{f669dc2bef3a4b80b1838c8625e2a8bb,
title = "Real-world efficacy: Intravenous palonosetron three-drug regimen for chemotherapy-induced nausea and vomiting with highly emetogenic chemotherapy",
abstract = "Aim: Real-world palonosetron effectiveness was evaluated in an antiemetic regimen with highly emetogenic chemotherapy (HEC). Patients & methods: In this Phase IV, prospective, multicenter observational study, HEC-treated cancer patients received palonosetron, a neurokinin 1 receptor antagonist, and dexamethasone. Primary objective was to assess complete response (CR) for acute (≤24 h), delayed and overall (≤120 h) chemotherapy-induced nausea and vomiting. Results: Of 159 patients, 65.4{\%} had breast cancer, 64.8{\%} received anthracycline (doxorubicin)-plus-cyclophosphamide-containing chemotherapy; 155 completed one HEC cycle. CR was 60.0{\%} acute, 39.4{\%} delayed and 34.8{\%} overall, and then increased (all phases) in 69 patients completing four HEC cycles. Anthracycline (doxorubicin) plus cyclophosphamide-receiving patients had especially low CR. Conclusion: Even within a recommended three-drug antiemetic regimen, palonosetron may provide suboptimal chemotherapy-induced nausea and vomiting control with HEC in real-world settings.",
author = "Lee Schwartzberg and Trent McLaughlin and Geller, {Robert B.} and Gabrail, {Nashat Y.} and Marks, {Stanley M.}",
year = "2018",
month = "12",
day = "1",
doi = "10.2217/cer-2018-0089",
language = "English (US)",
volume = "7",
pages = "1161--1170",
journal = "Journal of Comparative Effectiveness Research",
issn = "2042-6305",
publisher = "Future Medicine Ltd.",
number = "12",

}

TY - JOUR

T1 - Real-world efficacy

T2 - Intravenous palonosetron three-drug regimen for chemotherapy-induced nausea and vomiting with highly emetogenic chemotherapy

AU - Schwartzberg, Lee

AU - McLaughlin, Trent

AU - Geller, Robert B.

AU - Gabrail, Nashat Y.

AU - Marks, Stanley M.

PY - 2018/12/1

Y1 - 2018/12/1

N2 - Aim: Real-world palonosetron effectiveness was evaluated in an antiemetic regimen with highly emetogenic chemotherapy (HEC). Patients & methods: In this Phase IV, prospective, multicenter observational study, HEC-treated cancer patients received palonosetron, a neurokinin 1 receptor antagonist, and dexamethasone. Primary objective was to assess complete response (CR) for acute (≤24 h), delayed and overall (≤120 h) chemotherapy-induced nausea and vomiting. Results: Of 159 patients, 65.4% had breast cancer, 64.8% received anthracycline (doxorubicin)-plus-cyclophosphamide-containing chemotherapy; 155 completed one HEC cycle. CR was 60.0% acute, 39.4% delayed and 34.8% overall, and then increased (all phases) in 69 patients completing four HEC cycles. Anthracycline (doxorubicin) plus cyclophosphamide-receiving patients had especially low CR. Conclusion: Even within a recommended three-drug antiemetic regimen, palonosetron may provide suboptimal chemotherapy-induced nausea and vomiting control with HEC in real-world settings.

AB - Aim: Real-world palonosetron effectiveness was evaluated in an antiemetic regimen with highly emetogenic chemotherapy (HEC). Patients & methods: In this Phase IV, prospective, multicenter observational study, HEC-treated cancer patients received palonosetron, a neurokinin 1 receptor antagonist, and dexamethasone. Primary objective was to assess complete response (CR) for acute (≤24 h), delayed and overall (≤120 h) chemotherapy-induced nausea and vomiting. Results: Of 159 patients, 65.4% had breast cancer, 64.8% received anthracycline (doxorubicin)-plus-cyclophosphamide-containing chemotherapy; 155 completed one HEC cycle. CR was 60.0% acute, 39.4% delayed and 34.8% overall, and then increased (all phases) in 69 patients completing four HEC cycles. Anthracycline (doxorubicin) plus cyclophosphamide-receiving patients had especially low CR. Conclusion: Even within a recommended three-drug antiemetic regimen, palonosetron may provide suboptimal chemotherapy-induced nausea and vomiting control with HEC in real-world settings.

UR - http://www.scopus.com/inward/record.url?scp=85058016576&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=85058016576&partnerID=8YFLogxK

U2 - 10.2217/cer-2018-0089

DO - 10.2217/cer-2018-0089

M3 - Article

VL - 7

SP - 1161

EP - 1170

JO - Journal of Comparative Effectiveness Research

JF - Journal of Comparative Effectiveness Research

SN - 2042-6305

IS - 12

ER -